Please login to the form below

Not currently logged in
Email:
Password:

Kymriah

This page shows the latest Kymriah news and features for those working in and with pharma, biotech and healthcare.

Yescarta gains first FDA approval for indolent follicular lymphoma

Yescarta gains first FDA approval for indolent follicular lymphoma

Also approved for the treatment of large B-cell lymphoma is Novartis’ rival CAR-T therapy Kymriah (tisagenlecleucel) and Bristol Myers Squibb’s (BMS) Breyanzi (lisocabtagene maraleucel), which are both approved ... An approval in the first-line

Latest news

More from news
Approximately 14 fully matching, plus 64 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 18 partially matching documents found.

Latest from PMHub

  • Understanding the evolving CAR-T market

    In August 2017, Novartis made history after receiving FDA approval for Kymriah, the world’s first chimeric antigen receptor T-cell (CAR-T) therapy. ... But, Novartis could not retain a monopoly in for long. After the approval of Kymriah, investors

  • Precision paediatrics: Treating patients with CAR-T

    There are a number of trials being undertaken throughout the world, but the first licensed product, Novartis’ Kymriah, is now available for the treatment of leukaemia and is live at GOSH.

  • Training the next generation of biotech leaders

    In August, Novartis’ revolutionary CAR-T therapy, Kymriah, was approved. This was quickly followed by the approval of Kite’s Yescarta in October. ... Kymriah, which make it into routine practice as a first-line treatment.

More from PMHub
Approximately 0 fully matching, plus 3 partially matching documents found.

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
EPG Health

REACH, ENGAGE & MEASURE HCPs ONLINE - Accomplish meaningful engagement via Medthority (www.medthority.com), a trusted independent medical website. Support the...

Latest intelligence

01 PME-APR21 Cover.jpg
Virtual congresses: video thrilled the cardio tsar
Chris Ross explores the key learnings from a year of virtual congresses...
When Will We Be Back To Normal?
The definitive question of 2021, whether you’re a homeschooling parent, a homebound professional, a wanderer with nowhere to go… or all three at once....
How to tell your healthcare story.
Healthcare research is not a simple story and the people in charge of those moments need to be careful about the story that they tell....

Infographics